RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

    NEXT STORY
    Predictive Genetic Testing & Consumer/Wellness Genomics: World Market Anticipated to Witness a CAGR of 13.9% Over 2019-2025
    PREV STORY
    Sharps Compliance Reports Fiscal 2019 Fourth Quarter Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting

    author_avatar
    NASDAQ Market News

    Kansas University Medical Center and iSage Rx Receive Blue Cross and Blue Shield of Kansas City (Blue KC) Outcomes Grant to Study Insulin Optimization

    Insulin-Dependent Patients Will Be Enrolled in Clinical Trial Using iSage’s FDA Cleared Insulin Titration ...

    author_avatar
    NASDAQ Market News

    Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update

    author_avatar
    NASDAQ Market News